Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: Implications for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 4, 2011, Pages 819-833

  Bihaqi, Syed Waseem ^a   Huang, Hui ^b   Wu, Jinfang ^a   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

aging; Alzheimer's disease; DNA methylation; gene expression; histone modifications; Pb

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; LEAD; METHYL CPG BINDING PROTEIN 2;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; HAPLORHINI; HISTONE MODIFICATION; INFANT; LIFESPAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; UPREGULATION;

EID: 84455193330     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111013     Document Type: Article

References (63)

1. Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68, 1-11
2. Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M (1999) Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 56, 234-240 (Pubitemid 29125131)
3. Van Erp TG, Saleh PA, Rosso IM, Huttunen M, Lonnqvist J, Pirkola T, Salonen O, Valanne L, Poutanen VP, Standertskjold-Nordenstam CG, Cannon TD (2002) Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers. Am J Psychiatry 159, 1514-1520 (Pubitemid 35006731)
4. Boksa P, El-Khodor BF (2003) Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev 27, 91-101 (Pubitemid 36535392)
5. Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT (2004) Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 127B, 51-59 (Pubitemid 38542313)
6. Bird A (1992) The essentials of DNA methylation. Cell 70, 5-8
7. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209-213 (Pubitemid 16016411)
8. Jones PL, Jan Veenstra GC, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19, 187-191 (Pubitemid 28248804)
9. Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15, 172-183 (Pubitemid 36332192)
10. Tanzi RE, Bertram L (2008) Alzheimers disease: The latest suspect. Nature 454, 706-708
11. Selkoe DJ (1991) Amyloid protein and Alzheimers disease. Sci Am 265, 68-78
12. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimers disease: a new hypothesis. Curr Alzheimer Res 3, 81-90
13. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS (2003) A critical analysis of new molecular targets and strategies for drug developments in Alzheimers disease. Curr Drug Targets 4, 97-112 (Pubitemid 36553583)
14. Goedert M, Spillantini MG (2006) A century of Alzheimers disease. Science 314, 777-781
15. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122 (Pubitemid 36975801)
16. Liddell MB, Lovestone S, Owen MJ (2001) Genetic risk of Alzheimers disease: advising relatives. Br J Psychiatry 178, 7-11 (Pubitemid 32055638)
17. Migliore L, Coppede F (2009) Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667, 82-97
18. Barker DJ (1999) Fetal origins of cardiovascular disease. Ann Med 31(Suppl 1), 3-6 (Pubitemid 29209697)
19. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ (1989) Weight in infancy and death from ischaemic heart disease. Lancet 2, 577-580 (Pubitemid 19216205)
20. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nat Rev Genet 8, 253-262 (Pubitemid 46439287)
21. Payton M, Riggs KM, Spiro AS,Weiss ST,HuH(1998) Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol 20, 19-27 (Pubitemid 28102872)
22. Weisskopf MG, Proctor SP, Wright RO, Schwartz J, Spiro A, 3rd, Sparrow D, Nie H, Hu H (2007) Cumulative lead exposure and cognitive performance among elderly men. Epidemiology 18, 59-66 (Pubitemid 46005910)
23. Weisskopf M, Wrigh R, Schwartz J, Spiro A, Sparrow D, Aro A, Hu H (2004) Cumulative lead exposure and prospective change in cognition among elderly men. Am J Epidemiol 160, 1184-1193 (Pubitemid 39628059)
24. Wright RO, Tsaih SW, Schwartz J, Spiro A, 3rd, Mcdonald K, Weiss ST, Hu H (2003) Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology 14, 713-718 (Pubitemid 40417020)
25. Weuve J, Korrick SA, Weisskopf MG, Ryan LM, Schwartz J, Nie H, Grodstein F, Hu H (2009) Cumulative exposure to lead in relation to cognitive function in older women. Environ Health Perspect 117, 574-580
26. Schmidtke K, Hermeneit S (2008) High rate of conversion to Alzheimers disease in a cohort of amnestic MCI patients. Int Psychogeriatr 20, 96-108 (Pubitemid 350256058)
27. Niklowitz WJ, Mandybur TI (1975) Neurofibrillary changes following childhood lead encephalopathy. J Neuropathol Exp Neurol 34, 445-455
28. HaraguchiT, Ishizu H,TakehisaY,KawaiK,Yokota O,Terada S, Tsuchiya K, Ikeda K, Morita K, Horike T, Kira S, Kuroda S (2001) Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNTC): the possibility of lead neurotoxicity. Neuroreport 12, 3887-3890 (Pubitemid 33152418)
29. Momcilovic B, Alkhatib HA, Duerre JA, Cooley M, Long WM, Harris TR, Lykken GI (2001) Environmental lead-210 and bismuth-210 accrue selectively in the brain proteins in Alzheimer disease and brain lipids in Parkinson disease. Alzheimer Dis Assoc Disord 15, 106-115 (Pubitemid 32525451)
30. Dosunmu R, Wu J, Adwan L, Maloney B, Basha MR, McPherson CA, Harry GJ, Rice DC, Zawia NH, Lahiri DK (2009) Lifespan profiles of Alzheimers disease-associated genes and products in monkeys and mice. J Alzheimers Dis 18, 211-230
31. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, MaloneyB, Chen D, Lahiri DK, Zawia NH (2008) Alzheimers disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28, 3-9
32. Rice DC (1990) Lead-induced behavioral impairment on a spatial discrimination reversal task in monkeys exposed during different periods of development. Toxicol Appl Pharmacol 106, 327-333
33. Rice DC (1992) Effect of lead during different developmental periods in the monkey on concurrent discrimination performance. Neurotoxicology 13, 583-592
34. Dignam JD, Lebovitz RM, Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11, 1475-1489
35. Vaissiere T, Sawan C, Herceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659, 40-48
36. Urdinguio RG, Sanchez-Mut JV, EstellerM(2009) Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8, 1056-1072
37. Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther K (1988) The promoter of Alzheimers disease amyloid A4 precursor gene. EMBO J 7, 2807-2813
38. Cavallaro RA, Fuso A, DAnselmi F, Seminara L, Scarpa S (2006) The effect of S-adenosylmethionine on CNS gene expression studied by cDNA microarray analysis. J Alzheimers Dis 9, 415-419 (Pubitemid 44253356)
39. Castillo SO, Baffi JS, Palkovits M, Goldstein DS, Kopin IJ, Witta J, Magnuson MA, Nikodem VM (1998) Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci 11, 36-46 (Pubitemid 28235178)
40. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH (2005) The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25, 823-829 (Pubitemid 40170996)
41. Bakheet SA, Basha MR, Cai H, Zawia NH (2007) Lead exposure: expression and activity levels of Oct-2 in the developing rat brain. Toxicol Sci 95, 436-442 (Pubitemid 46152616)
42. Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med 12, 133-148
43. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimers disease. Nat Neurosci 11, 1311-1318
44. Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozach- Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19, 85-87 (Pubitemid 40069926)
45. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA (2003) A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3, 193-202 (Pubitemid 37328871)
46. Dubas TC, Stevenson A, Singhal RL, Hrdina PD (1978) Regional alterations of brain biogenic amines in young rats following chronic lead exposure. Toxicology 9, 185-190 (Pubitemid 8307331)
47. Leret ML, Garcia-Uceda F, Antonio MT (2002) Effects of maternal lead administration on monoaminergic, GABAergic and glutamatergic systems. Brain Res Bull 58, 469-473 (Pubitemid 35286770)
48. Kelly BL, Vassar R, Ferreira A (2005) Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem 280, 31746-31753 (Pubitemid 41291923)
49. Kuwano R, Miyashita A, Arai H, Asada T, ImagawaM, Shoji M, Higuchi S, Urakami K, Kakita A, Takahashi H, Tsukie T, Toyabe S, Akazawa K, Kanazawa I, IharaY(2006) Dynaminbinding protein gene on chromosome 10q is associated with late-onset Alzheimers disease. Hum Mol Genet 15, 2170-2182 (Pubitemid 43923406)
50. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM (2001) Mu-delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimers disease patients. Brain Res 893, 121-134 (Pubitemid 32171904)
51. McDowell J, Kitchen I (1988) Perinatal lead exposure alters the development of delta- but not mu-opioid receptors in rat brain. Br J Pharmacol 94, 933-937
52. Bucci C, Lutcke A, Steele-Mortimer O, Olkkonen VM, Dupree P, Chiariello M, Bruni CB, Simons K, ZerialM(1995) Co-operative regulation of endocytosis by three Rab5 isoforms. FEBS Lett 366, 65-71
53. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP (2003) Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 286, 355-365 (Pubitemid 36566447)
54. Watanabe D, Uchiyama K, Hanaoka K (2006) Transition of mouse de novo methyltransferases expression from Dnmt3b to Dnmt3a during neural progenitor cell development. Neuroscience 142, 727-737 (Pubitemid 44485924)
55. Francis YI, Fa M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimers disease. J Alzheimers Dis 18, 131-139
56. Berger SL (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12, 142-148 (Pubitemid 34219485)
57. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403, 41-45 (Pubitemid 30038513)
58. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T (2002) Active genes are tri-methylated at K4 of histone H3. Nature 419, 407-411
59. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G (2001) Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 293, 2453-2455 (Pubitemid 32917326)
60. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19, 187-191 (Pubitemid 28248804)
61. Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471-481 (Pubitemid 27154412)
62. Feng J, Fouse S, Fan G (2007) Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 61, 58R- 63R
63. Chen H, Ke Q, Kluz T, Yan Y, Costa M (2006) Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 26, 3728-3737 (Pubitemid 43726391)